Clinical and Translational Imaging

, Volume 1, Issue 3, pp 175–183

131I whole-body scan or 18FDG PET/CT for patients with elevated thyroglobulin and negative ultrasound?

  • Giorgio Treglia
  • Francesco Bertagna
  • Arnoldo Piccardo
  • Luca Giovanella
Review Article


The aim of this review is to discuss the current role of iodine-131 (131I) whole-body scanning (WBS) and fluorine-18-fluorodeoxyglucose positron emission tomography (18FDG PET) or PET/computed tomography (PET/CT) in the restaging of differentiated thyroid cancer (DTC), prompted by increasing thyroglobulin serum levels in patients with negative neck ultrasound. Studies in the literature which compared these two imaging methods are discussed in depth. 18FDG PET or PET/CT and 131I WBS may provide complementary information useful for the restaging of DTC patients, and the combined use of these methods should thus be considered to identify recurrent/metastatic DTC patients after total thyroidectomy. The accuracy of 18FDG PET/CT seems to be superior to that of 131I WBS and SPECT/CT in high-risk DTC.


Iodine-131 Fluorodeoxyglucose Positron emission tomography Thyroid cancer Restaging 


Thyroid tumors account for the vast majority of endocrine neoplasms and their incidence is increasing. Differentiated thyroid cancers (DTCs) are the most frequent thyroid neoplasms and usually have an excellent prognosis; conversely, more aggressive histological subtypes are less frequent and carry a worse prognosis. Recognizing recurrent/metastatic thyroid cancer has a significant impact on clinical decision-making and patient prognosis.

The aim of this review is to discuss the current role of iodine-131 (131I) whole-body scanning (WBS) and fluorine-18-fluorodeoxyglucose positron emission tomography (18FDG PET) or PET/computed tomography (PET/CT) in the restaging of DTC, prompted by increasing thyroglobulin (Tg) serum levels in patients with negative neck ultrasound (US). Furthermore, studies in the literature which compared these two imaging methods are discussed.

131I WBS in patients with detectable Tg levels and negative ultrasound

Diagnostic 131I WBS (DWBS) after thyroid-stimulating hormone (TSH) stimulation has been shown to have low sensitivity at 1-year follow-up of DTC [1, 2]. As a result, its role has been questioned over the past decade. Indeed, several authors have reported that the sensitivity of DWBS is no higher than 50 % of that of post-therapy 131I WBS (PTWBS) [3, 4, 5, 6, 7]. The ability of DWBS to reveal sites of disease has been found to be poor, and DWBS findings have not proved to be unequivocally related to serum Tg levels recorded after LT4 withdrawal or after TSH stimulation with recombinant human TSH (Tg-off levels) [1]. In particular, no correlation has been observed between Tg-off <10 ng/ml and DWBS [8]. Furthermore, in 10–15 % of DTC patients, high levels of Tg may be found despite negative DWBS [6, 9]. DWBS can only confirm successful thyroid remnant ablation, but it is unable to detect new pathological sites of disease that were not detected by PTWBS 1 year earlier [1]. Considering the well-known indolent behavior of DTC, it is likely that metastases detected by DWBS were already present at the time of ablation and already visualized by PTWBS [8]. In other words, when pathological uptake outside the thyroid bed is not detected by PTWBS, DWBS at 1-year follow-up is not necessary in low-risk DTC patients with undetectable Tg under LT4 (Tg-on) and negative neck US [10]. The best markers of complete ablation are considered to be undetectable serum Tg-off levels and normal neck US [11], and patients with undetectable Tg-off levels 1 year after ablation are reported to have an excellent outcome, regardless of residual thyroid bed uptake on DWBS [12]. However, American Thyroid Association (ATA) guidelines reported by Cooper et al. [10] still recommended DWBS in combination with stimulated Tg in high-risk patients with negative basal Tg and US after ablation. This application was recently addressed by Rosario et al. [8] who reported that DWBS can, however, be avoided in high-risk DTC patients with negative initial PTWBS and neck US disease and Tg-on levels <1 ng/ml.

In this diagnostic scenario, the population of DWBS-negative and Tg-positive DTC patients at 1-year follow-up examination is growing. Therefore, localizing the Tg-producing lesions correctly in these patients, to determine the proper treatment, is considered an increasingly important challenge [5, 6, 7].

Morphological imaging techniques, such as US and CT, are well-established methods of identifying neck and thoracic tumor localizations, respectively [13], especially in the presence of Tg-off values above 5 ng/ml. In particular, US can guide fine-needle aspiration cytology and/or Tg measurement in the aspirate. The added value of US is also related to the possibility of detecting cervical lymph node metastases, even in patients with undetectable Tg-off levels [10]. However, cases with detectable Tg-off levels, negative DWBS, and negative morphological findings are not infrequently reported. In these cases, empirical therapy with 131I should be considered to better detect sites of disease and for the treatment of disease not amenable to surgery [10]. The characteristics of the patient and the tumor must be taken into account before administering further empirical 131I therapy. In particular, age, tumor dimension (T), lymph node involvement (N), DTC subtype, and serum Tg-off levels are important factors in predicting the efficacy of further 131I therapy. On one hand, old age and aggressive subtypes are more often related to low 131I avidity of the tumor; while on the other hand, it must be remembered that greater T and N values are associated with a higher possibility of locoregional and distant metastases [14].

The two main (Tg-based) factors taken as the basis for proposing a second empirical 131I treatment are a post-ablation WBS with foci of uptake outside the thyroid bed and Tg-off levels above 10 ng/ml [15]; moreover, it has been suggested that a corresponding Tg rhTSH level would be 5 ng/ml [10]. If, on these grounds, a second 131I treatment is administered, 60 to 80 % of PTWBSs show uptake sites outside the thyroid bed, indicating tumor sites [5, 6, 7]. This confirms the intrinsic diagnostic utility of PTWBS in DTC patients with high Tg-off levels and no further evidence of disease. The highest sensitivity of PTWBS is often found in young patients (<45 years old) affected by a nonaggressive DTC subtype, in whom the percentage of false-negative results on DWBS is more often related to the small dimensions of metastatic lesions [7] than to a reduced capability of the 131I uptake mechanism. The principal sites of metastatic disease revealed by PTWBS in cases with negative morphological imaging, e.g., neck US and chest CT, are the cervical lymph nodes and lungs [5, 6, 7]. In this setting, the administration of a second dose of 131I ranging from 3,700 to 11,100 MBq [6] can have a considerable diagnostic and therapeutic significance. PTWBS may allow sites of metastasis to be identified before they emerge clinically some years later and may, at the same time, lead to partial or complete remission, especially in the case of small lung metastases [6, 16]. With regard to small cervical lymph nodes, PTWBS may be helpful, above all, in identifying the “culprit” cervical level warranting further lymph node dissection [15]. In this anatomical district, the retropharyngeal lymph nodes, which are not identifiable on US, are the principal sites of mismatching findings between US and PTWBS [10].

However, the key question that has arisen in recent years is that which patients need a further empirical 131I therapy and when this therapy should be performed. As reported by Padovani et al. [17], in the absence of structural disease, Tg-on levels may continue to decline over time after 131I administration, independently of other therapies. Moreover, the time needed to achieve undetectable Tg-on levels depends on the initial risk stratification. As previously demonstrated, Tg-on <1 ng/ml is achieved within 2 years of ablation in 84 % of low-risk patients, but in only 39 % of high-risk patients [18]. Since the natural history of intermediate and high-risk DTC patients is characterized by a slow decline in Tg-on levels over time, a conservative approach may be suggested for high-risk DTC patients with persistent stable Tg-on levels and no evidence of structural disease [17]. In the absence of any evidence of structural disease on conventional imaging (CI) (e.g., CT, US), additional empirical 131I therapy should be reserved for those DTC patients in whom the Tg-on value rises over time after ablation. This approach may reduce the possibility of administering further, inappropriate therapies to patients who are likely to show a late response to initial treatment.

18FDG PET or PET/CT in patients with detectable Tg levels after thyroidectomy

The literature contains increasing evidence of the usefulness of 18FDG PET or PET/CT in patients with thyroid tumors [19]. 18FDG is the most used PET tracer in oncology; this glucose analog is trapped by cells via the glucose transporters (GLUTs). Overexpression of GLUTs is particularly prevalent in aggressive thyroid tumors; in addition, overexpression of hexokinase-1 promotes 18FDG uptake in thyroid cancer cells [20].

DTC cells expressing the sodium–iodine symporter take up radioiodine; as cells dedifferentiate and the disease becomes more aggressive, their ability to concentrate iodine is lost (leading to reduced radioiodine uptake) and cellular glucose metabolism is activated (with increased 18FDG uptake) [20]. This pattern of differential tracer uptake was defined as the “flip-flop phenomenon” by Feine [21] in 1995. However, contrary to what the original name suggested, differential tracer uptake is not absolute. Patients with thyroid cancer can have a positive 131I-WBS with negative 18FDG PET, the opposite pattern, or a mixed pattern where some lesions show radioiodine uptake, other lesions show 18FDG uptake, and some lesions may show a different degree of uptake of both tracers [22].

According to the ATA guidelines, 18FDG PET and PET/CT are currently considered most valuable in the work-up of DTC patients who present post-thyroidectomy, with increasing serum Tg levels and negative 131I-WBS [10]. If no disease sites are identified on CI or 131I-WBS or Tg levels are elevated out of proportion to the minor disease found on CI, 18FDG PET or PET/CT should be performed to detect recurrent or metastatic disease [10, 22].

A meta-analysis of the diagnostic accuracy of 18FDG PET and PET/CT in DTC patients who presented with elevated serum Tg post-thyroidectomy and negative 131I-WBS reported a good diagnostic accuracy of these methods with pooled sensitivity and specificity values of 88.5 and 84.7 %, respectively. The pooled values of sensitivity increased when only 18FDG PET/CT studies were considered in the analysis (93.5 %), demonstrating a superior diagnostic accuracy of PET/CT compared to PET only [23].

Clinical evidence is emerging that the performance of 18FDG PET and PET/CT for the detection of Tg-positive and radioiodine-negative metastases of DTC is also improved after TSH stimulation (either by hormone withdrawal or rhTSH administration) [24]; however, the clinical significance of this superior diagnostic performance remains uncertain.

The current ATA guidelines suggest that 18FDG PET or PET/CT should be performed when Tg levels are >10 ng/mL [10]. However, no clear cutoff value of Tg has, as yet, been established in clinical practice; indeed, although the proportion of true-positive 18FDG-PET findings increases with elevated Tg levels, true-positive findings have also been reported in 10–20 % of DTC patients with Tg levels <10 ng/mL [22, 25]. A recent article suggested that both serum Tg levels and Tg doubling time independently predicted a positive 18FDG PET/CT scan in patients with biochemical recurrence of DTC. The accuracy of 18FDG PET/CT significantly improved when the serum Tg level was above 5.5 ng/mL during LT4 treatment or when the Tg doubling time was <1 year, irrespective of the absolute Tg value [26].

In daily practice, the decision on when to perform 18FDG PET or PET/CT in patients with recurrent DTC should be tailored to the single patient, considering not only Tg levels and 131I WBS findings, but also, on the basis of clinical and histopathological features, their individual risk [22].

Additional clinical uses of 18FDG PET or PET/CT in DTC have been reported, i.e., the use of these techniques as prognostic tools for identifying which patients with known distant metastases are at highest risk for disease-specific mortality [10, 27]. 18FDG PET or PET/CT are also used as selection tools for identifying patients unlikely to respond to additional radioiodine therapy, and they may allow the measurement of post-treatment response following external beam irradiation, surgical resection, embolization, or systemic therapy [10].

Low-risk patients with DTC are very unlikely to require 18FDG PET or PET/CT as part of their initial staging or follow-up. Moreover, at present, 18FDG PET and PET/CT are not recommended for preoperative assessment of DTC [10].

Conversely, in patients with more aggressive thyroid cancers (such as Hürthle cell carcinoma, aggressive variants of DTC, poorly differentiated thyroid carcinomas, and anaplastic carcinomas), which usually show low or absent radioiodine uptake, 18FDG PET and PET/CT are very useful methods for determining the extent of metastatic disease [28, 29] and for prognostic purposes; in the subset of patients with advanced disease, these imaging methods may also be helpful for treatment response assessment [10, 30].

Comparison of 131I WBS and 18FDG PET or PET/CT

Several authors have compared 131I-WBS and 18FDG PET or PET/CT results in patients with DTC with suspected metastases [31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44].

Direct comparisons of diagnostic accuracy

Grunwald et al. [31] evaluated the clinical significance of 18FDG PET and compared the results obtained using this technique with those obtained using 131I WBS. The sensitivity of 18FDG PET was found to be 75 % for the whole patient group (n = 222) and 85 % for the group with negative radioiodine scan (n = 166). The specificity was 90 % in the whole patient group. The sensitivity and specificity of 131I WBS were 50 and 99 %, respectively. When the results of 18FDG PET and 131I-WBS were combined, tumor tissue was missed in only 7 % of cases [31].

These findings were confirmed by Shiga et al. [32] who compared these two methods in 32 DTC patients. The number of lesions detected was 47; 87 % of the lesions were detected by both methods, but 18FDG PET uptake was concordant with 131I uptake in only 38 % of the lesions [32].

Hsu et al. [33] evaluating 15 patients with local invasive and/or aggressive DTC found that 18FDG PET was useful for detecting dedifferentiated lesions and was superior to 131I WBS in detecting residual cervical or mediastinal lesions and suspected small metastatic foci in the lung. 18FDG PET was inferior to 131I WBS in detecting diffuse lung metastases and distant bone metastases [33].

Iwata et al. [34] compared 18FDG PET and PTWBS in 19 patients. A total of 32 lesions were diagnosed as metastases; 96.9 % of the lesions were detected by at least one of the two modalities. Small lung metastases were not visualized by either modality in one patient. No false-positive lesions were identified by PTWBS. 18FDG PET and PTWBS revealed a total of 26 (81.3 %) and 22 (68.8 %) lesions, respectively. 18FDG PET was positive in 17 (78.3 %) out of 22 131I WBS-positive lesions, and also in 9 (90 %) out of 10 PTWBS-negative lesions. When the size of metastases was compared between 18FDG-positive and negative groups, the maximal diameter of 18FDG-positive lesions was found to be significantly greater than that of the 18FDG-negative lesions. The 18FDG-positive and PTWBS-positive lesions were significantly larger than both the 18FDG-negative and PTWBS-positive lesions and the 18FDG-positive and PTWBS-negative lesions. Only 18 lesions (56.3 %) showed concordant results between 18FDG PET and 131I uptake. Thus, there was no significant association between 131I uptake and 18FDG uptake [34].

In a study performed by Caleo et al. [36] in 13 DTC patients after thyroidectomy, 18FDG PET and 131I WBS yielded concordant negative results in the majority (77 %) of patients; the two imaging techniques gave concordant positive results in just one patient. In three patients, the results were discordant [36].

Oh et al. [37] compared the performance of 131I WBS, 131I SPECT/CT, and 18FDG PET/CT in the detection of distant metastases of DTC; 140 patients with 258 foci of suspected distant metastases were evaluated. The imaging modalities showed the following sensitivity, specificity, and accuracy values on patient-based analyses: 65, 55, and 59 % for 131I WBS; 65, 95, and 85 % for 131I SPECT/CT, and 61, 98, and 86 % for 18FDG PET/CT, respectively. Lesion-based analyses demonstrated that both 131I SPECT/CT and 18FDG PET/CT were superior to 131I WBS in all patient groups; 131I SPECT/CT was superior to 131I WBS and 18FDG PET/CT in patients who received a single challenge of radioiodine therapy, whereas 18FDG PET/CT was superior to 131I WBS and 131I SPECT/CT in patients who received multiple challenges [37].

The complementary role of these methods was confirmed by Nagamachi et al. [38] who, in 70 patients, compared the capacity of 131I-WBS and 18FDG PET/CT to detect postoperative DTC metastases. On the patient-basis analysis, the detectability by 131I WBS and 18FDG PET/CT was 67.1 and 84.2 %, respectively. 131I-WBS provided information complementary to that provided by 18FDG PET/CT in 11 of the 70 (15.7 %) cases. On the organ-basis analysis, 131I WBS was found to be the best detector of lymph node metastases (72.4 %), while 18FDG PET/CT was superior to 131I WBS for detecting bone metastases (85.7 versus 71.4 %, respectively) and lung metastases (94.1 versus 62.7 %, respectively) [38].

Overall, the literature suggests that 18FDG PET (or PET/CT) and 131I WBS provide complementary information for detecting metastases in postoperative DTC patients. 131I WBS is useful for determining the differentiation of tumor lesions, identifying thyroid remnants, and looking for distant metastases; while 18FDG PET (or PET/CT) is useful in cases of dedifferentiated thyroid carcinoma in which 131I WBS and Tg measurements are unable to detect tumor lesions. Furthermore, 18FDG PET (or PET/CT) has been shown to be a valuable diagnostic tool for the detection not only of 131I-negative lesions, but also of 131I-positive lesions of metastatic DTC (Figs. 1, 2, 3).
Fig. 1

131I WBS (a), 18FDG PET (b) and axial 18FDG PET/CT (C1C3) images in a 48-year-old female patient with increased Tg levels after thyroidectomy for a high-risk DTC. 131I WBS was negative, whereas 18FDG PET and PET/CT showed increased radiopharmaceutical uptake corresponding to lung metastases (arrows) (color figure online)

Fig. 2

131I WBS (a) and 18FDG PET (b) in a 70-year-old male patient with increased Tg levels after thyroidectomy for a DTC. 131I WBS detected increased tracer uptake corresponding to local recurrence and pulmonary lesions. 18FDG PET detected an additional lung lesion missed by 131I WBS (red arrow), whereas other lesions showed similar (orange arrows) or lower or absent radiopharmaceutical uptake compared to 131I WBS (yellow arrows) (color figure online)

Fig. 3

PTWBS in anterior (a1) and posterior (a2) view, axial 131I SPECT/CT (a3, a4), 18FDG PET (b1) and axial 18FDG PET/CT (b2b4) images in a 65-year-old male patient with increased Tg levels after thyroidectomy for a DTC. PTWBS detected increased 131I uptake corresponding to bone metastases on a right rib (red arrow) and a dorsal vertebra (yellow arrow). 18FDG PET/CT detected an additional bone lesion in a lumbar vertebra (green arrow) (color figure online)

Thus, the combination of 131I WBS and 18FDG PET (or PET/CT) should be considered when seeking to detect metastatic thyroid cancer after total thyroidectomy.

Other findings from the comparison between 131I WBS and 18FDG PET or PET/CT

Compared with DWBS and PTWBS, 18FDG PET scans are more likely to reveal uptake outside the thyroid bed and to correlate with the disease stage and long-term outcome, as demonstrated by Al-Zahrani et al. [35]. These authors compared 18FDG PET with DWBS and PTWBS to assess its prognostic value in 26 newly diagnosed DTC cases. Overall, 18 18FDG PET scans (69.2 %) were positive, showing a total of 40 foci; while eight 18FDG PET scans (30.8 %) were negative. The corresponding 26 DWBS were all positive and showed a total of 47 foci. DWBS and PTWBS showed similar foci in the 24 patients who had ablation therapy. In contrast to the 18FDG PET scans, which showed 26 foci of uptake (65 %) outside the thyroid bed, on DWBS, 45 foci (95.7 %) were in the thyroid bed; while two foci (4.3 %) were in cervical lymph nodes and no focus was seen outside the neck area. A clear correlation was found between the 18FDG PET results, the stage of the disease, and the long-term outcome; seven of the eight negative 18FDG PET scans were in stage I, while all patients with a disease stage higher than I (six patients) had positive scans. Over a median of 30 months, seven of the eight patients (87.5 %) with negative 18FDG PET scans were in remission compared with only eight (44.4 %) of those with positive 18FDG PET [35].

18FDG PET/CT can be recommended for papillary thyroid cancer (PTC) patients with detectable serum Tg levels to detect residual lymph node metastases, as described by Kaneko et al. [39]. These authors evaluated the incidence of residual lymph node metastases in 37 high-risk PTC patients receiving adjuvant 131I therapy, especially in those without 131I accumulation and assessed the clinical usefulness of 18FDG PET/CT for detecting these lesions. A total of 33 lesions in nine patients were diagnosed as residual lymph node metastases. 18FDG accumulated in all of the lesions, but 19 (57.6 %) of them had no 131I accumulation. These results indicated that residual lymph node metastases were relatively common in high-risk PTC patients receiving adjuvant 131I therapy whose serum Tg levels remained detectable, and these lesions often had no 131I accumulation [39].

Yoshio et al. [40] evaluated the local efficacy of 131I therapy for 18FDG PET/CT-positive lesions in patients with DTC after total thyroidectomy. Their analysis was performed on 44 lesions in 37 patients. In the group with positive accumulation on 18FDG PET/CT and negative accumulation on 131I (F+/I− group), 16 lesions (70 %) were found to be increased while seven (30 %) showed no change or reduction. In the group with positive accumulation for both 18F-FDG and 131I (F+/I+ group), five lesions (63 %) were increased and three (37 %) showed no change or reduction after 131I therapy. The tendency to increase in size was not found to differ significantly between the F+/I− and the F+/I+ groups. Lesions which showed positive accumulations on 18FDG PET/CT had a greater tendency to increase in size, suggesting that the 18FDG-avid lesions were resistant to radioactive iodine therapy with or without 131I uptake [40].

As recently shown by Piccardo et al. [41], 18FDG PET/CT could detect new radioiodine-negative metastases in advanced DTC patients with unchanged positive 131I WBS and increasing Tg levels. These authors studied stage-IV DTC patients with elevated Tg levels associated with positive 131I WBS. On suspicion of non-iodine concentrating additional metastases, 20 stage-IV DTC patients with increasing Tg levels and stable positive PTWBS were enrolled. Conventional imaging procedures, including neck US, bone scintigraphy, and CT, were performed before 18FDG PET/CT. The 18FDG PET/CT was positive in 16 out of 20 patients (80 %). In nine patients (45 %), it detected a larger number of tumor recurrences/metastatic sites than were detected on 131I WBS + CI [41].

The sensitivity of empirical 131I administration and subsequent 131I WBS versus 18FDG PET/CT in patients who had a normal post-ablation 131I WBS was assessed in a recent article by Leboulleux et al. [42]. Thirty-four DTC patients with a normal post-ablation 131I WBS underwent empirical 131I administration and 18FDG PET/CT. A total of 75 lesions were found in 23 patients, distributed in 36 organs. The sensitivities for the detection of individual lesions and for the diagnosis of metastatic organs were 88 and 97 % for 18FDG PET/CT and 16 and 22 % for post-empirical 131I WBS, respectively. 18FDG PET/CT was abnormal in 22 patients, five of whom also had an abnormal post-empirical 131I WBS. Only one patient was found to have an abnormal post-empirical 131I WBS and a normal 18FDG PET/CT. These authors concluded that in patients with suspicion of recurrence based on the Tg level after a normal post-ablation 131I WBS, 18FDG PET/CT, rather than post-empirical 131I WBS, should be used to localize the disease. Empirical 131I should be used only in patients with no significant 18FDG uptake [42].

18FDG PET performed concurrently with 131I ablation can detect lymph node metastases in which radioiodine does not accumulate and may influence the management and treatment options for DTC patients, as Iwano et al. [43] have shown. These authors evaluated the ability of 18FDG PET, performed concurrently with initial 131I ablation, to detect lymph node metastases, and also examined its role in the management of DTC patients. Fifty-four patients underwent both 18FDG PET and subsequent 131I ablation. 18FDG PET was positive in 25 sites in 18 patients (33 %). Only five out of 16 lymph node metastases (31 %) that were 18FDG PET-positive were also positive on 131I WBS. The success rate of Tg-negative after ablation was significantly lower in patients with 18FDG PET-positive scans than in those with 18FDG PET-negative scans [43].

18FDG PET/CT as an initial staging method has a high impact on the management of patients with high-risk DTC, as recently demonstrated by Rosenbaum-Krumme et al. [44] in a study of 90 consecutive patients with either extensive or metastasized high-risk DTC who received 18FDG PET after the first 131I treatment. 18FDG PET/CT was positive in 26 patients (29 %) and negative in 64 patients (71 %). These findings were compared with the results of 131I WBS. In the 26 patients with 18FDG PET/CT-positive lesions, the lesions were found to be both iodine- and 18FDG-positive in 7 patients, 18FDG-positive only in 15; while in 4 patients some lesions were 18FDG-positive and some were iodine-positive [44].

Comparison of the radiation dose of 131I WBS and 18FDG PET

Diagnostic accuracy apart, it is important to underline the difference in the radiation dose between DWBS, PTWS, and 18FDG PET.

For example 185 MBq of 131I, administered for a DWBS, and 5550 MBq of 131I, administered for a PTWBS, correspond to radiation doses of 11 and 330 mSv, respectively. The administration of 300 MBq of 18FDG corresponds to a radiation dose of about 6 mSv.


This analysis of the literature leads us to conclude that 18FDG PET or PET/CT and 131I WBS may provide complementary information useful in the restaging of DTC patients. Accordingly, the combined use of these methods should thus be considered to identify recurrent/metastatic DTC patients after total thyroidectomy. The accuracy of 18FDG PET/CT seems to be superior to that of 131I WBS in high-risk DTC.


Conflict of interest

G. Treglia, F. Bertagna, A. Piccardo, L. Giovanella declare that they have no conflict of interest related to the publication of this article.

Human and Animal Studies

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M (2000) Is diagnostic iodine-131 useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175–178PubMedCrossRefGoogle Scholar
  2. 2.
    Mazzaferri EL, Kloos RT (2002) Is diagnostic iodine-131 recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490–1498PubMedCrossRefGoogle Scholar
  3. 3.
    Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW (1994) Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78:629–634PubMedCrossRefGoogle Scholar
  4. 4.
    Tenenbaum F, Corone C, Schlumberger M, Parmentier C (1996) Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer 32A:1262PubMedCrossRefGoogle Scholar
  5. 5.
    Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A (1987) Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888–1891PubMedGoogle Scholar
  6. 6.
    Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C (1988) Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790–1794PubMedGoogle Scholar
  7. 7.
    Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488–1492PubMedCrossRefGoogle Scholar
  8. 8.
    Rosario PW, Furtado Mde S, Mineiro Filho AF, Lacerda RX, Calsolari MR (2012) Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence. Thyroid 22:1165–1169PubMedCrossRefGoogle Scholar
  9. 9.
    Ashcraft MW, Van Herle AJ (1981) The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 71:806–814PubMedCrossRefGoogle Scholar
  10. 10.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214PubMedCrossRefGoogle Scholar
  11. 11.
    Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Lambert E, Lind P, Pacini F, Reiners C, Franco FS, Toft A, Wiersinga WM (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105–112PubMedCrossRefGoogle Scholar
  12. 12.
    Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A (2002) Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499–1501PubMedCrossRefGoogle Scholar
  13. 13.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803PubMedCrossRefGoogle Scholar
  14. 14.
    Mazzaferri EL, Kloos RT (2001) Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463PubMedCrossRefGoogle Scholar
  15. 15.
    Schlumberger M, Mancusi F, Baudin E, Pacini F (1997) 131I therapy for elevated thyroglobulin levels. Thyroid 7:273–276PubMedCrossRefGoogle Scholar
  16. 16.
    Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK (2003) Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol 58:421–427CrossRefGoogle Scholar
  17. 17.
    Padovani RP, Robenshtok E, Brokhin M, Tuttle RM (2012) Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 22:778–783PubMedCrossRefGoogle Scholar
  18. 18.
    Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349PubMedCrossRefGoogle Scholar
  19. 19.
    Treglia G, Muoio B, Giovanella L, Salvatori M (2013) The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol 270:1783–1787PubMedCrossRefGoogle Scholar
  20. 20.
    Giovanella L (2012) Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Expert Rev Endocrinol Metab 7:35–43CrossRefGoogle Scholar
  21. 21.
    Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W (1995) 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34:127–134PubMedGoogle Scholar
  22. 22.
    Abraham T, Schöder H (2011) Thyroid cancer–indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 41:121–138PubMedCrossRefGoogle Scholar
  23. 23.
    Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY, Sun F, Luo XG (2009) Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 30:639–650PubMedCrossRefGoogle Scholar
  24. 24.
    Ma C, Xie J, Lou Y, Gao Y, Zuo S, Wang X (2010) The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur J Endocrinol 163:177–183PubMedCrossRefGoogle Scholar
  25. 25.
    Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA (2012) Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck 34:626–631PubMedCrossRefGoogle Scholar
  26. 26.
    Giovanella L, Trimboli P, Verburg FA, Treglia G, Piccardo A, Foppiani L, Ceriani L (2013) Thyroglobulin levels and thyroglobulin doubling time independently predict a positive (18)F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-013-2370-6 PubMedGoogle Scholar
  27. 27.
    Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498–505PubMedCrossRefGoogle Scholar
  28. 28.
    Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY (2012) Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 37:121–127PubMedCrossRefGoogle Scholar
  29. 29.
    Treglia G, Annunziata S, Muoio B, Salvatori M, Ceriani L, Giovanella L (2013) The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. Int J Endocrinol 2013:856189Google Scholar
  30. 30.
    Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M (2010) 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37:2277–2285PubMedCrossRefGoogle Scholar
  31. 31.
    Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547–1552PubMedCrossRefGoogle Scholar
  32. 32.
    Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y, Tamaki N (2001) Comparison of (18)F-FDG (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 42:414–419PubMedGoogle Scholar
  33. 33.
    Hsu CH, Liu RS, Wu CH, Chen SM, Shih LS (2002) Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer. J Formos Med Assoc 101:459–467PubMedGoogle Scholar
  34. 34.
    Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, Nakamoto Y, Higashi T, Saga T, Konishi J (2004) Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 31:491–498PubMedCrossRefGoogle Scholar
  35. 35.
    Al-Zahrani AS, Abouzied ME, Salam SA, Mohamed G, Rifai A, Al Sugair A, Amin T (2008) The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer. Eur J Endocrinol 158:683–689PubMedCrossRefGoogle Scholar
  36. 36.
    Caleo O, Maurea S, Klain M, Salvatore B, Storto G, Mancini M, Pace L, Salvatore M (2008) Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose. Radiol Med 113:278–288PubMedCrossRefGoogle Scholar
  37. 37.
    Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, Kang SR, Kim DY, Song HC, Bom HS, Min JJ (2011) Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹8F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 38:1459–1468PubMedCrossRefGoogle Scholar
  38. 38.
    Nagamachi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, Futami S, Arita H, Kuroki M, Nakada H, Uchino N, Tamura S, Kawai K (2011) Comparison of diagnostic and prognostic capabilities of 18F-FDG-PET/CT, ¹³¹I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol 29:413–422PubMedCrossRefGoogle Scholar
  39. 39.
    Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi H, Sasaki M, Hatakenaka M, Honda H (2010) Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. Clin Nucl Med 35:6–11PubMedCrossRefGoogle Scholar
  40. 40.
    Yoshio K, Sato S, Okumura Y, Katsui K, Takemoto M, Suzuki E, Katayama N, Kaji M, Kanazawa S (2011) The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas. Clin Nucl Med 36:113–117PubMedCrossRefGoogle Scholar
  41. 41.
    Piccardo A, Foppiani L, Morbelli S, Bianchi P, Barbera F, Biscaldi E, Altrinetti V, Villavecchia G, Cabria M (2011) Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan? Q J Nucl Med Mol Imaging 55:57–65PubMedGoogle Scholar
  42. 42.
    Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M (2012) Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum Tg levels. Thyroid 22:832–838PubMedCrossRefGoogle Scholar
  43. 43.
    Iwano S, Kato K, Ito S, Tsuchiya K, Naganawa S (2012) FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer. Ann Nucl Med 26:207–213PubMedCrossRefGoogle Scholar
  44. 44.
    Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I (2012) 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 39:1373–1380PubMedCrossRefGoogle Scholar

Copyright information

© Italian Association of Nuclear Medicine and Molecular Imaging 2013

Authors and Affiliations

  • Giorgio Treglia
    • 1
  • Francesco Bertagna
    • 2
  • Arnoldo Piccardo
    • 3
  • Luca Giovanella
    • 1
  1. 1.Department of Nuclear Medicine and PET/CT CenterOncology Institute of Southern SwitzerlandBellinzonaSwitzerland
  2. 2.Department of Nuclear MedicineUniversity of Brescia and Spedali Civili di BresciaBresciaItaly
  3. 3.Nuclear Medicine UnitGalliera HospitalGenoaItaly

Personalised recommendations